APA (7th ed.) Citation

E, C., YF, S., JF, L., & W, W. (2024). Post-marketing safety concerns with elagolix: A disproportionality analysis of the FDA adverse event reporting system. Expert opinion on drug safety, 23(12), 1545. https://doi.org/10.1080/14740338.2024.2351451

Chicago Style (17th ed.) Citation

E, Chang, Shi YF, Liu JF, and Wei W. "Post-marketing Safety Concerns with Elagolix: A Disproportionality Analysis of the FDA Adverse Event Reporting System." Expert Opinion on Drug Safety 23, no. 12 (2024): 1545. https://doi.org/10.1080/14740338.2024.2351451.

MLA (9th ed.) Citation

E, Chang, et al. "Post-marketing Safety Concerns with Elagolix: A Disproportionality Analysis of the FDA Adverse Event Reporting System." Expert Opinion on Drug Safety, vol. 23, no. 12, 2024, p. 1545, https://doi.org/10.1080/14740338.2024.2351451.